Truist Financial Issues Pessimistic Forecast for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price objective cut by equities researchers at Truist Financial from $21.00 to $18.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective points to a potential upside of 288.35% from the company’s current price.

Other research analysts have also issued reports about the company. Wedbush reaffirmed an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday. Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. Finally, Bank of America dropped their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $19.30.

Y-mAbs Therapeutics Stock Performance

Shares of Y-mAbs Therapeutics stock traded down $0.33 on Wednesday, hitting $4.64. The stock had a trading volume of 195,646 shares, compared to its average volume of 467,754. The stock has a 50 day moving average of $6.46 and a 200 day moving average of $10.62. The firm has a market capitalization of $207.60 million, a P/E ratio of -8.58 and a beta of 0.65. Y-mAbs Therapeutics has a twelve month low of $4.25 and a twelve month high of $18.19.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The business had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the previous year, the firm earned ($0.02) earnings per share. Equities analysts expect that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Acorn Capital Advisors LLC acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $22,408,000. Caligan Partners LP boosted its holdings in Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after acquiring an additional 613,175 shares in the last quarter. State Street Corp grew its stake in Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares during the period. Infinitum Asset Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at approximately $1,218,000. Finally, Paradigm Biocapital Advisors LP raised its position in shares of Y-mAbs Therapeutics by 3.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock worth $33,171,000 after purchasing an additional 150,000 shares during the period. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.